1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.2.1. Research Assumptions
1.2.2. Project Methodology
1.2.3. Forecast Methodology
1.2.4. Robust Quality Control
1.2.5. Key Considerations
1.2.5.1. Demographics
1.2.5.2. Economic Factors
1.2.5.3. Government Regulations
1.2.5.4. Supply Chain
1.2.5.6. COVID Impact / Related Factors
1.2.5.7. Market Access
1.2.5.8. Healthcare Policies
1.2.5.9. Industry Consolidation
1.3 Key Questions Answered
1.4. Chapter Outlines
3. INTRODUCTION
3.1. Context and Background
3.2. Cell Therapies
3.3. Cell Therapy Manufacturing
3.4. Key Challenges Associated with Manufacturing Cell Therapies
3.5. Overview of Automated and Closed Cell Processing Systems
3.5.1. Need for Automated and Closed Cell Processing in Cell Therapy Manufacturing
3.5.2. Advantages and Affiliated Challenges
3.6. Key Growth Drivers and Roadblocks
3.7. Recent Developments and Upcoming Trends
4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Automated and Closed Cell Therapy Processing Systems: Overall Market Landscape
4.2.1. Analysis by Cell Processing Step
4.2.2. Analysis by Types of Cells
4.2.3. Analysis by Type of Culture
4.2.4. Analysis by Scale of Operation
4.2.5. Analysis by Key Features
4.2.6. Analysis by Application Area
4.2.7. Analysis by Regulatory Certifications / Accreditations
4.2.8. Analysis by End User
4.3. Automated and Closed Cell Therapy Processing Systems: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Type of Support Service(s) Offered
4.3.4. Analysis by Location of Headquarters
5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions / Key Parameters
5.3. Methodology
5.4. Product Competitiveness Analysis
5.4.1. Automated and Closed Cell Processing Systems for Apheresis
5.4.2. Automated and Closed Cell Processing Systems for Separation
5.4.3. Automated and Closed Cell Processing Systems for Expansion
5.4.4. Automated and Closed Cell Processing Systems for Harvest
5.4.5. Automated and Closed Cell Processing Systems for Fill Finish
5.4.6. Automated and Closed Cell Processing Systems for Cryopreservation
5.4.7. Automated and Closed Cell Processing Systems for Thawing
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Cytiva
6.2.1. Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Pall
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. Terumo BCT
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Financial Information
6.4.4. Recent Developments and Future Outlook
6.5 ThermoGenesis
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Financial Information
6.5.4. Recent Developments and Future Outlook
7. PARTNERSHIPS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Automated and Closed Cell Therapy Processing Systems: Recent Partnerships
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Type of Therapy
7.3.4. Analysis by Cell Processing Step
7.3.5. Analysis by Type of Automated and Closed Cell Processing Systems
7.3.6. Analysis by Partner’s Focus Area
7.3.7. Most Active Players: Analysis by Number of Partnerships
7.3.8. Geographical Analysis
7.3.8.1. Country-Wise Distribution
7.3.8.2. Intercontinental and Intracontinental Agreements
8. BIG PHARMA INITIATIVES IN AUTOMATED AND CLOSED CELL THERAPY PROCESSING SYSTEMS DOMAIN
8.1. Chapter Overview
8.2. Initiatives Undertaken by Big Pharma Players
8.2.1. Initiatives Undertaken by AbbVie
8.2.2. Initiatives Undertaken by Bristol Myers Squibb
8.2.3. Initiatives Undertaken by Gilead Sciences
8.2.4. Initiatives Undertaken by GlaxoSmithKline
8.2.5. Initiatives Undertaken by Johnson & Johnson
8.2.6. Initiatives Undertaken by Novartis
8.2.7. Initiatives Undertaken by Roche
8.2.8. Initiatives Undertaken by Sanofi
8.2.9. Initiatives Undertaken by Takeda Pharmaceutical
8.2.10. Summary of Big Pharma Initiatives
9. LIKELY PARTNER
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Automated and Closed Cell Therapy Processing Systems: Potential Strategic Partners for Cell Therapy Development
9.3.1. Dendritic Cell Therapy
9.3.2. Stem Cell Therapy
9.3.3. T-cell Therapy
9.3.4. Natural Killer Cell Therapy
9.4. Automated and Closed Cell Therapy Processing Systems: Potential Strategic Partners for Cell Therapy Manufacturing
9.4.1. Dendritic Cell Therapy
9.4.2. Stem Cell Therapy,
9.4.3. T-cell Therapy
9.4.4. Natural Killer Cell Therapy
10. CASE STUDY: COST BENEFIT ANALYSIS USING PARTIALLY AUTOMATED AND FULLY AUTOMATED SYSTEMS
10.1. Chapter Overview
10.2. Comparative Analysis of Manual, Partially Automated and Fully Automated Cell Processing Systems
10.3. Likely Cost Saving Potential for Kymriah®
10.4. Likely Cost Saving Potential for Yescarata®
10.5. Cost Saving Potential of Fully Automated Processing Systems: Regional Trends
10.6. Concluding Remarks
11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Overall Automated and Closed Cell Therapy Processing Systems Market, Till 2035
11.3.1. Overall Automated and Closed Cell Therapy Processing Systems Market: Distribution by Cell Therapy Processing Step
11.3.1.1. Automated and Closed Cell Therapy Processing Systems Market for Apheresis, Till 2035
11.3.1.2. Automated and Closed Cell Therapy Processing Systems Market for Separation, Till 2035
11.3.1.3. Automated and Closed Cell Therapy Processing Systems Market for Expansion, Till 2035
11.3.1.4. Automated and Closed Cell Therapy Processing Systems Market for Harvest, Till 2035
11.3.1.5. Automated and Closed Cell Therapy Processing Systems Market for Fill / Finish, Till 2035
11.3.1.6. Automated and Closed Cell Therapy Processing Systems Market for Cryopreservation, Till 2035
11.3.1.7. Automated and Closed Cell Therapy Processing Systems Market for Thawing, Till 2035
11.3.2. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Scale of Operation
11.3.2.1. Automated and Closed Cell Therapy Processing Systems Market for Pre-clinical / Clinical Operations, Till 2035
11.3.2.2. Automated and Closed Cell Therapy Processing Systems Market for Commercial Operations, Till 2035
11.3.3. Automated and Closed Cell Therapy Processing Systems Market: Distribution by End User
11.3.3.1. Automated and Closed Cell Therapy Processing Systems Market for Hospitals / Medical Centers / Clinics / Research Institutes / Academic Institutes, Till 2035
11.3.3.2. Automated and Closed Cell Therapy Processing Systems Market for Cell Therapy Manufacturers / Developers, Till 2035
11.3.4. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Key Geographic Regions
11.3.4.1. Automated and Closed Cell Therapy Processing Systems Market in North America, Till 2035
11.3.4.2. Automated and Closed Cell Therapy Processing Systems Market in Europe, Till 2035
11.3.4.3. Automated and Closed Cell Therapy Processing Systems Market in Asia-Pacific, Till 2035
11.3.4.4. Automated and Closed Cell Therapy Processing Systems Market in Latin America (LATAM), Till 2035
11.3.4.5. Automated and Closed Cell Therapy Processing Systems Market in Middle East North America (MENA), Till 2035
12. CONCLUSION
12.1. Chapter Overview
12.2. Key Takeaways
LIST OF FIGURES
Figure 3.1. Key Steps Involved in Manufacturing of Cell Therapies
Figure 3.2. Key Considerations while Automating Cell Therapy Manufacturing Process
Figure 3.3. Role of Automated and Closed Systems across Each Cell Therapy Processing Step
Figure 3.4. Advantages offered by Automated and Closed Cell Processing Systems
Figure 3.5. Challenges Associated with Automated and Closed Cell Processing Systems
Figure 3.6. Growth Drivers and Roadblocks in the Automated and Closed Systems Market
Figure 4.1. Automated and Closed Cell Therapy Processing Systems: Distribution by Cell Processing Step
Figure 4.2. Automated and Closed Cell Therapy Processing Systems: Distribution by Types of Cells
Figure 4.3. Automated and Closed Cell Therapy Processing Systems: Distribution by Type of Culture
Figure 4.4. Automated and Closed Cell Therapy Processing Systems: Distribution by Scale of Operation
Figure 4.5. Automated and Closed Cell Therapy Processing Systems: Distribution by Key Features
Figure 4.6. Automated and Closed Cell Therapy Processing Systems: Distribution by Application Area
Figure 4.7. Automated and Closed Cell Therapy Processing Systems: Distribution by Regulatory Certifications / Accreditations
Figure 4.8. Automated and Closed Cell Therapy Processing Systems: Distribution by End Users
Figure 4.9. Automated and Closed Cell Therapy Processing System Providers: Distribution by Year of Establishment
Figure 4.10. Automated and Closed Cell Therapy Processing System Providers: Distribution by Company Size
Figure 4.11. Automated and Closed Cell Therapy Processing System Providers: Distribution by Type of Support Services Offered
Figure 4.12. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location
Figure 4.13. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location (Country-Wise)
Figure 4.14. Leading Developers: Distribution by Number of Automated and Closed Cell Therapy Processing Systems
Figure 5.1. Product Competitiveness Analysis: Automated and Closed Systems for Cell Apheresis
Figure 5.2. Product Competitiveness Analysis: Automated and Closed Systems for Cell Separation
Figure 5.3. Product Competitiveness Analysis: Automated and Closed Systems for Cell Expansion
Figure 5.4. Product Competitiveness Analysis: Automated and Closed Systems for Cell Harvesting
Figure 5.5. Product Competitiveness Analysis: Automated and Closed Systems for Fill Finish
Figure 5.6. Product Competitiveness Analysis: Automated and Closed Systems for Cryopreservation
Figure 5.7. Product Competitiveness Analysis: Automated and Closed Systems for Thawing
Figure 6.1. Terumo BCT: Annual Revenues, Since FY 2016
Figure 6.2. ThermoGenesis: Annual Revenues, Since FY 2016
Figure 7.1. Recent Partnerships: Cumulative Distribution by Year of Partnership
Figure 7.2. Recent Partnerships: Distribution by Type of Partnership Model Adopted
Figure 7.3. Recent Partnerships: Year-wise Trend by Type of Partnership Model Adopted
Figure 7.4. Recent Partnerships: Distribution by Type of Therapy
Figure 7.5. Recent Partnerships: Distribution by Type of Therapy and Type of Partnership Model Adopted
Figure 7.6. Recent Partnerships: Distribution by Cell Processing Step
Figure 7.7. Recent Partnerships: Distribution by Automated and Closed Cell Processing System
Figure 7.8. Recent Partnerships: Distribution by Type of Partner
Figure 7.9. Recent Partnerships: Distribution by Type of Cell Processing Step and Developer
Figure 7.10. Recent Partnerships: Most Active Players
Figure 7.11. Recent Partnerships: Country-Wise Distribution
Figure 7.12. Recent Partnerships: Intercontinental and Intracontinental Distribution
Figure 8.1. Big Pharma Initiatives Summary
Figure 10.1. Cost Saving Analysis: Comparative Analysis of Manual, Partially Automated and Fully Automated Processing Systems, Till 2035
Figure 10.2. Cost Saving Potential of Fully Automated Processing Systems Based on Number of Patients
Figure 10.3. Cost Saving Potential of Fully Automated Processing Systems Across Different Regions
Figure 11.1. Overall Automated and Closed Cell Therapy Processing Systems Market, Till 2035 (USD Million)
Figure 11.2. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Cell Therapy Processing Step (USD Million)
Figure 11.3. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Apheresis Systems, Till 2035 (USD Million)
Figure 11.4. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Separation Systems, Till 2035 (USD Million)
Figure 11.5. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Expansion Systems, Till 2035 (USD Million)
Figure 11.6. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Harvesting Systems, Till 2035 (USD Million)
Figure 11.7. Automated and Closed Cell Therapy Processing Systems Market: Share of Fill Finish Systems, Till 2035 (USD Million)
Figure 11.8. Automated and Closed Cell Therapy Processing Systems Market: Share of Cryopreservation Systems, Till 2035 (USD Million)
Figure 11.9. Automated and Closed Cell Therapy Processing Systems Market: Share of Thawing Systems, Till 2035 (USD Million)
Figure 11.10. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Scale of Operation (USD Million)
Figure 11.11. Automated and Closed Cell Therapy Processing Systems Market: Share of Preclinical / Clinical Scale Operations, Till 2035 (USD Million)
Figure 11.12. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Operations, Till 2035 (USD Million)
Figure 11.13. Automated and Closed Cell Therapy Processing Systems Market: Distribution by End User (USD Million)
Figure 11.14. Automated and Closed Cell Therapy Processing Systems Market: Share of Hospitals / Medical Centers / Clinics / Research Institutes / Academic Institutes, Till 2035 (USD Million)
Figure 11.16. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Organizations, Till 2035 (USD Million)
Figure 11.17. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Key Geographical Regions (USD Million)
Figure 11.18. Automated and Closed Cell Therapy Processing Systems Market: Share of North America, Till 2035 (USD Million)
Figure 11.19. Automated and Closed Cell Therapy Processing Systems Market: Share of Europe, Till 2035 (USD Million)
Figure 11.20. Automated and Closed Cell Therapy Processing Systems Market: Share of Asia-Pacific, Till 2035 (USD Million)
Figure 11.21. Automated and Closed Cell Therapy Processing Systems Market: Share of LATAM, Till 2035 (USD Million)
Figure 11.22. Automated and Closed Cell Therapy Processing Systems Market: Share of MENA, Till 2035 (USD Million)
LIST OF TABLES
Table 3.1. Cell and Advanced Therapies: Key Applications
Table 3.2. Assessment of Key Cell Therapy Manufacturing Steps
Table 4.1. List of Automated and Closed Cell Therapy Processing Systems: Information on Cell Processing Step
Table 4.2. List of Automated and Closed Cell Therapy Processing Systems: Information on Types of Cells
Table 4.3. List of Automated and Closed Cell Therapy Processing Systems: Information on Type of Culture
Table 4.4. List of Automated and Closed Cell Therapy Processing Systems: Information on Scale of Operation
Table 4.5. List of Automated and Closed Cell Therapy Processing Systems: Information on Key Features
Table 4.6. List of Automated and Closed Cell Therapy Processing Systems: Information on Application Area
Table 4.7. List of Automated and Closed Cell Therapy Processing Systems: Information on Regulatory Certifications / Accreditations Obtained
Table 4.8. List of Automated and Closed Cell Therapy Processing Systems: Information on End Users
Table 4.9. List of Automated and Closed Cell Therapy Processing System Providers
Table 4.10. List of Automated and Closed Cell Therapy Processing System Providers: Information on Type of Support Service(s) Offered
Table 6.1. Cytiva: Key Highlights
Table 6.2. Cytiva: Product Portfolio
Table 6.3. Pall: Key Highlights
Table 6.4. Pall: Product Portfolio
Table 6.5. Terumo BCT: Key Highlights
Table 6.6. Terumo BCT: Product Portfolio
Table 6.7. Terumo BCT: Recent Developments and Future Outlook
Table 6.8. ThermoGenesis: Key Highlights
Table 6.9. ThermoGenesis: Product Portfolio
Table 6.10. ThermoGenesis: Recent Developments and Future Outlook
Table 7.1. Automated and Closed Cell Processing Systems: List of Partnerships, Since 2016
Table 8.1. Automated and Closed Cell Processing Systems: List of Big Pharma Players
Table 9.1. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Dendritic Cell Therapy Developers
Table 9.2. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Stem Cell Therapy Developers
Table 9.3. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: T-cell Therapy Developers
Table 9.4. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Natural Killer Cell Therapy Developers
Table 9.5. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Dendritic Cell Therapy Manufacturers
Table 9.6. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Stem Cell Therapy Manufacturers
Table 9.7. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: T-cell Therapy Manufacturers
Table 9.8. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Natural Killer Cell Therapy Manufacturers
Table 10.1. Comparative Analysis of Manual, Partially Automated and Fully Automated Cell Processing Systems, Since 2020
Table 10.2. Cost Saving Potential of Fully Automated Systems
Table 14.1. Automated and Closed Cell Therapy Processing Systems: Distribution by Cell Processing Step
Table 14.2. Automated and Closed Cell Therapy Processing Systems: Distribution by Types of Cells
Table 14.3. Automated and Closed Cell Therapy Processing Systems: Distribution by Type of Culture
Table 14.4. Automated and Closed Cell Therapy Processing Systems: Distribution by Scale of Operation
Table 14.5. Automated and Closed Cell Therapy Processing Systems: Distribution by Key Features
Table 14.6. Automated and Closed Cell Therapy Processing Systems: Distribution by Application Area
Table 14.7. Automated and Closed Cell Therapy Processing Systems: Distribution by Regulatory Certifications / Accreditations
Table 14.8. Automated and Closed Cell Therapy Processing Systems: Distribution by End Users
Table 14.9. Automated and Closed Cell Therapy Processing System Providers: Distribution Year of Establishment
Table 14.10. Automated and Closed Cell Therapy Processing System Providers: Distribution by Company Size
Table 14.11. Automated and Closed Cell Therapy Processing System Providers: Distribution by Type of Support Services Offered
Table 14.12. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location
Table 14.13. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location (Country-Wise)
Table 14.14. Leading Developers: Distribution by Number of Automated and Closed Cell Therapy Processing Systems
Table 14.15. Terumo BCT: Annual Revenues, Since FY 2016
Table 14.16. ThermoGenesis: Annual Revenues, Since FY 2016
Table 14.17. Recent Partnerships: Cumulative Distribution by Year of Partnership
Table 14.18. Recent Partnerships: Distribution by Type of Partnership Model Adopted
Table 14.19. Recent Partnerships: Year-wise Trend by Type of Partnership Model Adopted
Table 14.20. Recent Partnerships: Distribution by Type of Therapy
Table 14.21. Recent Partnerships: Distribution by Type of Therapy and Type of Partnership Model Adopted
Table 14.22. Recent Partnerships: Distribution by Cell Processing Step
Table 14.23. Recent Partnerships: Distribution by Automated and Closed Cell Processing System
Table 14.24. Recent Partnerships: Distribution by Type of Partner
Table 14.25. Recent Partnerships: Distribution by Type of Cell Processing Step and Developer
Table 14.26. Recent Partnerships: Most Active Players
Table 14.27. Recent Partnerships: Country-Wise Distribution
Table 14.28. Recent Partnerships: Intercontinental and Intracontinental Distribution
Table 14.29. Big Pharma Initiatives Summary
Table 14.30. Cost Saving Analysis: Comparative Analysis of Manual, Partially Automated and Fully Automated Processing Systems, Till 2035
Table 14.31. Cost Saving Potential of Fully Automated Processing Systems Based on Number of Patients
Table 14.32. Cost Saving Potential of Fully Automated Processing Systems Across Different Regions
Table 14.33. Overall Automated and Closed Cell Therapy Processing Systems Market, Till 2035 (USD Million)
Table 14.34. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Cell Therapy Processing Step (USD Million)
Table 14.35. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Apheresis Systems, Till 2035 (USD Million)
Table 14.36. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Separation Systems, Till 2035 (USD Million)
Table 14.37. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Expansion Systems, Till 2035 (USD Million)
Table 14.38. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Harvesting Systems, Till 2035 (USD Million)
Table 14.39. Automated and Closed Cell Therapy Processing Systems Market: Share of Fill Finish Systems, Till 2035 (USD Million)
Table 14.40. Automated and Closed Cell Therapy Processing Systems Market: Share of Cryopreservation Systems, Till 2035 (USD Million)
Table 14.41. Automated and Closed Cell Therapy Processing Systems Market: Share of Thawing Systems, Till 2035 (USD Million)
Table 14.42. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Scale of Operation (USD Million)
Table 14.43. Automated and Closed Cell Therapy Processing Systems Market: Share of Preclinical / Clinical Scale Operations, Till 2035 (USD Million)
Table 14.44. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Operations, Till 2035 (USD Million)
Table 14.45. Automated and Closed Cell Therapy Processing Systems Market: Distribution by End User (USD Million)
Table 14.46. Automated and Closed Cell Therapy Processing Systems Market: Share of Hospitals / Medical Centers / Clinics / Research Institutes / Academic Institutes, Till 2035 (USD Million)
Table 14.47. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Organizations, Till 2035 (USD Million)
Table 14.48. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Key Geographical Regions (USD Million)
Table 14.49. Automated and Closed Cell Therapy Processing Systems Market: Share of North America, Till 2035 (USD Million)
Table 14.50. Automated and Closed Cell Therapy Processing Systems Market: Share of Europe, Till 2035 (USD Million)
Table 14.51. Automated and Closed Cell Therapy Processing Systems Market: Share of Asia-Pacific, Till 2035 (USD Million)
Table 14.52. Automated and Closed Cell Therapy Processing Systems Market: Share of LATAM, Till 2035 (USD Million)
Table 14.53. Automated and Closed Cell Therapy Processing Systems Market: Share of MENA, Till 2035 (USD Million)
